Eliem Therapeutics files for Nasdaq IPO to raise up to $80M after $140M private funding; to trade as ELYM

Eliem Therapeutics, a Redmond clinical-stage biotech developing treatments for pain and mood disorders, filed for a Nasdaq IPO under ticker ELYM seeking up to $80 million after raising $140 million in private funding this year. The company, founded in 2019 and led by CEO Bob Azelby, is advancing ETX-810 (phase 2a for neuropathic pain) and ETX-155 (for mood disorders and epilepsy).

No comments yet.